Home/Resources/ICH M4 eCTD Guide
REGULATORY GUIDE

ICH M4 eCTD Structure: Complete Implementation Guide

Step-by-step guide to structuring regulatory submissions using the ICH Common Technical Document format for global regulatory authorities

πŸ“˜ 15 min readβ€’For: Regulatory Affairs Professionalsβ€’Last updated: November 2025

Table of Contents

→1. Introduction to ICH M4→2. The Five-Module Structure→3. Module 1: Administrative Information→4. Module 2: CTD Summaries→5. Module 3: Quality→6. Module 4: Nonclinical Study Reports→7. Module 5: Clinical Study Reports→8. eCTD Technical Specifications→9. Agency-Specific Requirements→10. Best Practices & Pitfalls

Introduction to ICH M4

The ICH M4 guideline defines the Common Technical Document (CTD), a standardized format for organizing regulatory submission data. The CTD harmonizes the structure and format of applications across regulatory authorities in the US (FDA), Europe (EMA), Japan (PMDA), and other ICH regions.

Why ICH M4 Matters

  • βœ“ Global Consistency: Submit the same structure to multiple agencies
  • βœ“ Reduced Rework: Modules 2-5 are identical across regions
  • βœ“ Reviewer Efficiency: Regulators know exactly where to find information
  • βœ“ Industry Standard: Required by major regulatory authorities worldwide

ICH M4 Family of Guidelines

M4(R4)
Common Technical Document (CTD) Organization

Overall structure and organization of the five modules

M4Q(R1)
CTD - Quality

Module 3 (Quality) detailed structure and content requirements

M4S(R2)
CTD - Safety

Module 4 (Nonclinical) detailed structure and content

M4E(R2)
CTD - Efficacy

Module 5 (Clinical) detailed structure and content

eCTD vs. CTD

πŸ“„CTD (Paper-Based)

  • β€’ Physical binders and paper documents
  • β€’ Sequential page numbering
  • β€’ No hyperlinks or navigation
  • β€’ Difficult to update
  • β€’ Largely obsolete

πŸ’ΎeCTD (Electronic)

  • β€’ Electronic files (PDFs, XML)
  • β€’ Hierarchical folder structure
  • β€’ Hyperlinked navigation via XML backbone
  • β€’ Easy updates via sequences
  • β€’ Current standard

Note: This guide focuses on eCTD format as it is now required by FDA, EMA, PMDA, Health Canada, and most major regulatory authorities. The structural content follows ICH M4, but the technical implementation follows eCTD specifications (currently v4.0).

The Five-Module Structure

The CTD is organized into five modules. Modules 2-5 are common across all ICH regions, while Module 1 is region-specific.

CTD Module Overview

πŸ“‹

Module 1: Administrative Information & Prescribing Information

Region-Specific

Forms, labels, administrative documents (varies by region)

πŸ“Š

Module 2: Common Technical Document Summaries

Common

Quality, Nonclinical, and Clinical overviews and summaries

βš—οΈ

Module 3: Quality

Common

Drug substance, drug product, and quality data

πŸ”¬

Module 4: Nonclinical Study Reports

Common

Pharmacology, pharmacokinetics, and toxicology

πŸ₯

Module 5: Clinical Study Reports

Common

Clinical pharmacology, efficacy, and safety studies

Document Flow & Dependencies

The modules are designed to be read in a specific order, building from high-level summaries to detailed data:

1.
Module 2 (Summaries): Reviewers start here to get overview of quality, nonclinical, and clinical data
2.
Modules 3, 4, 5 (Detailed Reports): Reviewers dive into specific areas based on summary findings
3.
Cross-References: Summaries in Module 2 must reference detailed reports in Modules 3-5

Module 1: Administrative Information

πŸ“‹

Region-Specific Content

Module 1 varies significantly by regulatory authority

Module 1 contains administrative information and prescribing information specific to each region. Unlike Modules 2-5, Module 1 is NOT harmonized across ICH regions.

Module 1 by Region

πŸ‡ΊπŸ‡ΈModule 1 for FDA (United States)

Key Documents (Section 1.0 - 1.14):

  • β€’ 1.0: Cover letters
  • β€’ 1.2: Administrative information (FDA Form 356h, application type)
  • β€’ 1.3.1: FDA Form 1571 (for INDs) or Form 356h (for NDAs/BLAs)
  • β€’ 1.3.2: Other forms (3674, 3454, 3455, patent certifications)
  • β€’ 1.4: Debarment certification
  • β€’ 1.5: Field copy certification
  • β€’ 1.6: Patent information and exclusivity
  • β€’ 1.8: Financial disclosure
  • β€’ 1.11: Draft labeling (package insert, patient labeling)
  • β€’ 1.12: Risk evaluation and mitigation strategies (REMS)
  • β€’ 1.14: Environmental assessment or categorical exclusion

πŸ‡ͺπŸ‡ΊModule 1 for EMA (European Union)

Key Documents (Section 1.0 - 1.8):

  • β€’ 1.0: Cover letter, application form
  • β€’ 1.1: Comprehensive table of contents
  • β€’ 1.2: Application forms (varies by procedure: centralized, MRP, DCP)
  • β€’ 1.3: Product information (SmPC, labeling, package leaflet)
  • β€’ 1.4: Information about experts
  • β€’ 1.5: Specific requirements (orphan designation, pediatric investigation plan)
  • β€’ 1.6: Environmental risk assessment
  • β€’ 1.8: Information from reference member state (for MRP/DCP)

πŸ‡―πŸ‡΅Module 1 for PMDA (Japan)

Key Documents:

  • β€’ Application forms specific to PMDA
  • β€’ Proposed Japanese package insert (ζ·»δ»˜ζ–‡ζ›Έ)
  • β€’ Documentation of GMP/GCP/GLP compliance
  • β€’ Foreign regulatory status
  • β€’ Re-examination period application
  • β€’ Documentation for bridging studies (if applicable)

Important: Always consult the specific regulatory authority's guidance for Module 1 requirements. The documents, forms, and organization vary significantly between regions.

Module 2: CTD Summaries

πŸ“Š

High-Level Overviews for Reviewers

Critical summaries that guide the review process

Module 2 provides comprehensive summaries of the quality, nonclinical, and clinical data. This is typically the first module reviewers read, so clarity and completeness are essential.

Module 2 Structure

2.1 CTD Table of Contents

Comprehensive table of contents for the entire CTD (Modules 2-5). Includes hyperlinks to all documents in the submission.

2.2 CTD Introduction

Brief introduction to the product, submission, and regulatory history:

  • β€’ Product name (INN, proprietary name)
  • β€’ Dosage form, route of administration, strength
  • β€’ Pharmacological class and therapeutic indication
  • β€’ Prior regulatory submissions and approvals
  • β€’ Rationale for current application

2.3 Quality Overall Summary (QOS)

Detailed summary of Module 3 content (typically 50-100 pages):

  • β€’ 2.3.S: Drug substance (API) summary
  • β€’ 2.3.P: Drug product (finished dosage form) summary
  • β€’ 2.3.A: Appendices (facilities, adventitious agents for biologics)
  • β€’ 2.3.R: Regional information (if applicable)

2.4 Nonclinical Overview

Integrated overview of nonclinical data (typically 30-40 pages):

  • β€’ Overview of nonclinical testing strategy
  • β€’ Integrated analysis of pharmacology, pharmacokinetics, and toxicology
  • β€’ Critical findings and their interpretation
  • β€’ Justification for clinical trial design

2.5 Clinical Overview

Integrated overview of clinical data (typically 50-100 pages):

  • β€’ Product development rationale
  • β€’ Overview of biopharmaceutics and clinical pharmacology
  • β€’ Overview of efficacy
  • β€’ Overview of safety
  • β€’ Benefit-risk assessment
  • β€’ Literature references

2.6 Nonclinical Written and Tabulated Summaries

Detailed tabulated summaries of all nonclinical studies:

  • β€’ 2.6.1: Introduction
  • β€’ 2.6.2: Pharmacology written summary
  • β€’ 2.6.3: Pharmacology tabulated summary
  • β€’ 2.6.4: Pharmacokinetics written summary
  • β€’ 2.6.5: Pharmacokinetics tabulated summary
  • β€’ 2.6.6: Toxicology written summary
  • β€’ 2.6.7: Toxicology tabulated summary

2.7 Clinical Summary

Detailed summary of clinical program (typically 100-200 pages):

  • β€’ 2.7.1: Summary of biopharmaceutic studies and associated analytical methods
  • β€’ 2.7.2: Summary of clinical pharmacology studies
  • β€’ 2.7.3: Summary of clinical efficacy
  • β€’ 2.7.4: Summary of clinical safety
  • β€’ 2.7.5: References
  • β€’ 2.7.6: Synopses of individual studies

Key Writing Principles for Module 2

Stand-Alone Readability

Module 2 summaries should be comprehensive enough that a reviewer can understand the entire submission without reading Modules 3-5. Include sufficient detail and context.

Critical Analysis, Not Just Description

Don't simply repeat data from Modules 3-5. Provide integrated analysis, interpretation, and discussion of findings. Address potential concerns proactively.

Liberal Use of Cross-References

Reference specific sections in Modules 3-5 to allow reviewers to find detailed data easily. Use hyperlinks in eCTD format.

Tables and Figures

Use tables and figures extensively to present data clearly. Summary tables should integrate data from multiple studies for easy comparison.

Module 3: Quality

βš—οΈ

Chemistry, Manufacturing, and Controls (CMC)

Comprehensive quality data for drug substance and drug product

Module 3 contains detailed information on the manufacture and control of the drug substance (API) and drug product (finished dosage form). This follows the ICH M4Q guideline.

Module 3 Structure: The "S-P-A-R" Organization

S3.2.S - Drug Substance (API)

  • β€’ 3.2.S.1: General Information (nomenclature, structure, properties)
  • β€’ 3.2.S.2: Manufacture (manufacturers, manufacturing process, control of materials)
  • β€’ 3.2.S.3: Characterization (structure elucidation, impurities)
  • β€’ 3.2.S.4: Control of Drug Substance (specification, analytical procedures, validation)
  • β€’ 3.2.S.5: Reference Standards or Materials
  • β€’ 3.2.S.6: Container Closure System
  • β€’ 3.2.S.7: Stability (stability studies, post-approval protocols, data)

P3.2.P - Drug Product (Finished Dosage Form)

  • β€’ 3.2.P.1: Description and Composition
  • β€’ 3.2.P.2: Pharmaceutical Development (formulation, overages, physicochemical properties)
  • β€’ 3.2.P.3: Manufacture (manufacturers, batch formula, manufacturing process, controls)
  • β€’ 3.2.P.4: Control of Excipients (specifications, analytical procedures)
  • β€’ 3.2.P.5: Control of Drug Product (specification, analytical procedures, validation)
  • β€’ 3.2.P.6: Reference Standards or Materials
  • β€’ 3.2.P.7: Container Closure System
  • β€’ 3.2.P.8: Stability (stability studies, post-approval protocols, data)

A3.2.A - Appendices

  • β€’ 3.2.A.1: Facilities and Equipment
  • β€’ 3.2.A.2: Adventitious Agents Safety Evaluation (for biologics)
  • β€’ 3.2.A.3: Excipients (additional information beyond 3.2.P.4)

R3.2.R - Regional Information

  • β€’ Region-specific CMC information (if applicable)
  • β€’ Typically not used in harmonized submissions

Critical Module 3 Documents

3.2.P.2: Pharmaceutical Development

The "story" of product development - critical for QbD approaches:

  • β€’ Components of drug product (selection rationale)
  • β€’ Drug product development (formulation, process)
  • β€’ Manufacturing process development
  • β€’ Container closure system development
  • β€’ Microbiological attributes
  • β€’ Compatibility with reconstitution diluents

3.2.P.8 & 3.2.S.7: Stability

Must follow ICH Q1A-F stability guidelines:

  • β€’ Long-term stability (25Β°C/60% RH or 30Β°C/75% RH)
  • β€’ Accelerated stability (40Β°C/75% RH)
  • β€’ Intermediate conditions (if needed)
  • β€’ Stress conditions (photostability, temperature)
  • β€’ Data from β‰₯3 batches (pilot or commercial scale)
  • β€’ Minimum 6 months data at filing (12 months ideal)

ICH Quality Guidelines: Module 3 should comply with all relevant ICH Q guidelines (Q1-Q14), including stability testing, analytical validation, impurities control, and pharmaceutical development. Reference specific ICH guidelines where applicable.

Module 4: Nonclinical Study Reports

πŸ”¬

Pharmacology, Pharmacokinetics, and Toxicology

Full study reports supporting safety of the product

Module 4 contains complete study reports for all nonclinical studies. Organization follows ICH M4S (Safety) guideline, with studies grouped by discipline.

Module 4 Structure

4.2.1 Pharmacology

  • β€’ 4.2.1.1: Primary pharmacodynamics
  • β€’ 4.2.1.2: Secondary pharmacodynamics
  • β€’ 4.2.1.3: Safety pharmacology (cardiovascular, CNS, respiratory)
  • β€’ 4.2.1.4: Pharmacodynamic drug interactions

4.2.2 Pharmacokinetics

  • β€’ 4.2.2.1: Analytical methods and validation reports
  • β€’ 4.2.2.2: Absorption studies
  • β€’ 4.2.2.3: Distribution studies
  • β€’ 4.2.2.4: Metabolism studies
  • β€’ 4.2.2.5: Excretion studies
  • β€’ 4.2.2.6: Pharmacokinetic drug interactions
  • β€’ 4.2.2.7: Other pharmacokinetic studies

4.2.3 Toxicology

  • β€’ 4.2.3.1: Single-dose toxicity
  • β€’ 4.2.3.2: Repeat-dose toxicity (duration supporting clinical studies)
  • β€’ 4.2.3.3: Genotoxicity (Ames, in vitro chromosomal aberration, in vivo micronucleus)
  • β€’ 4.2.3.4: Carcinogenicity (2-year rodent studies if applicable)
  • β€’ 4.2.3.5: Reproductive and developmental toxicity
  • β€’ 4.2.3.6: Local tolerance
  • β€’ 4.2.3.7: Other toxicity studies (antigenicity, immunotoxicity, etc.)

GLP Compliance Requirements

Which Studies Require GLP?

βœ“ GLP Required:

  • β€’ Safety pharmacology
  • β€’ All toxicology studies
  • β€’ Genotoxicity studies
  • β€’ Carcinogenicity studies
  • β€’ Reproductive toxicity

β—‹ GLP Not Always Required:

  • β€’ Primary pharmacodynamics
  • β€’ Secondary pharmacodynamics
  • β€’ Most pharmacokinetic studies
  • β€’ Exploratory studies

Note: Each study report must include a statement regarding GLP compliance and the role of the Quality Assurance Unit.

ICH Safety Guidelines Referenced in Module 4

ICH S1A/B

Carcinogenicity Studies

Need, conduct, and evaluation

ICH S2(R1)

Genotoxicity Testing

Battery of tests required

ICH S3A/B

Toxicokinetics & PK

Integration with toxicology

ICH S4A

Chronic Toxicity Testing

Duration of studies

ICH S5(R3)

Reproductive Toxicology

Fertility, embryo-fetal, pre/postnatal

ICH S6(R1)

Biotechnology Products

Species selection, immunogenicity

ICH S7A/B

Safety Pharmacology

Core battery, supplemental studies

ICH S8

Immunotoxicity Studies

When to conduct

ICH S9

Nonclinical for Anticancer

Special considerations for oncology

ICH S10

Photosafety Evaluation

Phototoxicity assessment

Module 5: Clinical Study Reports

πŸ₯

Clinical Pharmacology, Efficacy, and Safety

Full clinical study reports supporting efficacy and safety

Module 5 contains complete clinical study reports for all clinical trials. Organization follows ICH M4E (Efficacy) guideline, with studies grouped by type and phase.

Module 5 Structure

5.2 Tabular Listing of All Clinical Studies

Complete list of all clinical studies (one line per study):

  • β€’ Study identifier, title, phase
  • β€’ Study population, number of subjects
  • β€’ Study design, objectives
  • β€’ Location in eCTD (cross-reference to Module 5 section)

5.3.1 Reports of Biopharmaceutic Studies

  • β€’ 5.3.1.1: Bioavailability (BA) study reports
  • β€’ 5.3.1.2: Comparative BA and bioequivalence (BE) study reports
  • β€’ 5.3.1.3: In vitro-in vivo correlation study reports
  • β€’ 5.3.1.4: Reports of bioanalytical and analytical methods

5.3.2 Reports of Studies Pertinent to Pharmacokinetics

  • β€’ Healthy subject PK studies
  • β€’ Patient PK studies
  • β€’ Intrinsic factor studies (renal/hepatic impairment, age, gender)
  • β€’ Extrinsic factor studies (drug-drug interactions, food effects)
  • β€’ Population PK studies

5.3.3 Reports of Human Pharmacodynamics Studies

  • β€’ Proof of concept studies
  • β€’ Dose-response exploration
  • β€’ Studies in healthy volunteers or patients

5.3.4 Reports of Human Pharmacokinetics and Pharmacodynamics

  • β€’ Integrated PK/PD studies

5.3.5 Reports of Efficacy and Safety Studies

The core clinical evidence (typically the largest section):

  • β€’ 5.3.5.1: Controlled studies pertinent to the claimed indication
  • β€’ 5.3.5.2: Uncontrolled studies
  • β€’ 5.3.5.3: Reports of analyses of data from more than one study
  • β€’ 5.3.5.4: Other clinical studies

5.3.6 Reports of Postmarketing Experience

  • β€’ For products already marketed in other regions

5.3.7 Case Report Forms and Individual Patient Listings

  • β€’ Case report forms (CRFs) - often provided electronically
  • β€’ Individual patient data listings for deaths, SAEs, discontinuations

ICH E3 Clinical Study Report Format

All clinical study reports in Module 5 should follow ICH E3 structure:

  1. 1. Title Page
  2. 2. Synopsis (2-3 page summary)
  3. 3. Table of Contents
  4. 4. List of Abbreviations
  5. 5. Ethics
  6. 6. Investigators and Study Administrative Structure
  7. 7. Introduction
  8. 8. Study Objectives
  9. 9. Investigational Plan
  10. 10. Study Patients
  11. 11. Efficacy Evaluation
  12. 12. Safety Evaluation
  13. 13. Discussion and Overall Conclusions
  14. 14. Tables, Figures, and Graphs Referred to but Not Included in the Text
  15. 15. Reference List
  16. 16. Appendices (protocol, sample CRF, technical details, patient data listings, etc.)

Integrated Summary of Safety (ISS) and Efficacy (ISE)

While not always required, integrated summaries provide powerful cross-study analyses:

  • ISS:
    Integrated Summary of Safety - Pools safety data across studies to identify rare adverse events and characterize the overall safety profile. Follow ICH E2F guidance.
  • ISE:
    Integrated Summary of Efficacy - Analyzes efficacy across studies to demonstrate consistency and robustness of treatment effect.

eCTD Technical Specifications

While ICH M4 defines the content structure, eCTD specifications define the technical format for electronic submission. The current standard is eCTD v4.0.

eCTD Folder Structure

[Application Root]
β”œβ”€β”€ index.xml (root XML file)
β”œβ”€β”€ util/
β”‚   └── dtd/ (Document Type Definitions)
β”œβ”€β”€ m1/
β”‚   └── us/ (or eu, jp, etc.)
β”‚       β”œβ”€β”€ 10-cover/
β”‚       β”œβ”€β”€ 12-application-information/
β”‚       β”œβ”€β”€ 13-forms/
β”‚       └── ... (region-specific structure)
β”œβ”€β”€ m2/
β”‚   β”œβ”€β”€ 21-toc/
β”‚   β”œβ”€β”€ 22-introduction/
β”‚   β”œβ”€β”€ 23-quality-overall-summary/
β”‚   β”œβ”€β”€ 24-nonclinical-overview/
β”‚   β”œβ”€β”€ 25-clinical-overview/
β”‚   β”œβ”€β”€ 26-nonclinical-summaries/
β”‚   └── 27-clinical-summary/
β”œβ”€β”€ m3/
β”‚   β”œβ”€β”€ 32s-drug-substance/
β”‚   β”œβ”€β”€ 32p-drug-product/
β”‚   β”œβ”€β”€ 32a-appendices/
β”‚   └── 32r-regional/
β”œβ”€β”€ m4/
β”‚   β”œβ”€β”€ 42-study-reports/
β”‚   β”‚   β”œβ”€β”€ 421-pharmacology/
β”‚   β”‚   β”œβ”€β”€ 422-pharmacokinetics/
β”‚   β”‚   └── 423-toxicology/
β”‚   └── ...
└── m5/
    β”œβ”€β”€ 53-clinical-study-reports/
    β”‚   β”œβ”€β”€ 531-biopharm-studies/
    β”‚   β”œβ”€β”€ 532-pk-studies/
    β”‚   β”œβ”€β”€ 533-pd-studies/
    β”‚   β”œβ”€β”€ 534-pk-pd-studies/
    β”‚   β”œβ”€β”€ 535-efficacy-safety/
    β”‚   β”œβ”€β”€ 536-postmarketing/
    β”‚   └── 537-case-report-forms/
    └── ...

XML Backbone

The eCTD XML backbone provides the structure and navigation for the submission:

  • β†’
    index.xml: Root file that references all modules and their contents
  • β†’
    Document nodes: Each document (PDF, XML, etc.) is represented as a leaf node
  • β†’
    Metadata: Each node includes title, operation (new, replace, delete), checksum
  • β†’
    Hyperlinks: Cross-references within documents are maintained as hyperlinks

Sequence Concept

What is a Sequence?

An eCTD submission is organized into sequences. Each sequence represents a snapshot of the submission at a point in time:

  • β€’ Sequence 0000: Initial submission (IND, NDA, MAA)
  • β€’ Sequence 0001: First amendment/update
  • β€’ Sequence 0002: Second amendment/update
  • β€’ And so on...

Each new sequence only contains changed files (new, replace, delete operations), not the entire submission. Regulators build the complete submission by combining all sequences.

File Formats

Allowed Formats

  • β€’ PDF/A-1a or PDF/A-1b: Required for most documents
  • β€’ XML: For structured data (index.xml, study data)
  • β€’ MPEG-2, AVI, QuickTime: For videos
  • β€’ JPEG, PNG: For standalone images
  • β€’ RTF: For documents requiring editing (rare)

PDF Requirements

  • β€’ Must be searchable (OCR if scanned)
  • β€’ Hyperlinks must be functional
  • β€’ Bookmarks for navigation (optional but recommended)
  • β€’ No security restrictions (passwords, editing locks)
  • β€’ No JavaScript or executable content

Agency-Specific Requirements

While Modules 2-5 are harmonized, each agency has specific requirements for eCTD implementation:

πŸ‡ΊπŸ‡ΈFDA (United States)

  • β€’ Gateway: Electronic Submissions Gateway (ESG)
  • β€’ Mandatory: eCTD required for all NDAs, BLAs, ANDAs (since 2017-2018)
  • β€’ Validation: FDA provides free validation tools (Global Submission Tool - GST)
  • β€’ Study Data: CDISC datasets required (SDTM, ADaM) for Phase 2/3 studies
  • β€’ Granularity: Prefers individual study reports over compilations

πŸ‡ͺπŸ‡ΊEMA (European Union)

  • β€’ Gateway: EMA Gateway (CESP)
  • β€’ Mandatory: eCTD required for centralized procedure and many national procedures
  • β€’ Validation: Use EMA validation service before submission
  • β€’ Study Data: CDISC datasets increasingly expected
  • β€’ RMP: Risk Management Plan (RMP) required in Module 1.8
  • β€’ QRD: Product information must follow QRD template

πŸ‡―πŸ‡΅PMDA (Japan)

  • β€’ Gateway: PMDA eCTD Gateway
  • β€’ Mandatory: eCTD required for new applications
  • β€’ Validation: PMDA provides validation tools
  • β€’ Language: Module 1 in Japanese; Modules 2-5 can be English with Japanese summary
  • β€’ Bridging: Often requires ethnic factor studies comparing Japanese to non-Japanese data
  • β€’ Interview Form: Specific Japanese requirement for product information

πŸ‡¨πŸ‡¦Health Canada

  • β€’ Gateway: Common Electronic Submission Gateway (CESG)
  • β€’ Mandatory: eCTD required for most submission types
  • β€’ Module 1: Similar to FDA with Canadian-specific forms
  • β€’ Bilingual: Product monograph may need English and French versions

Best Practices & Common Pitfalls

Best Practices

βœ“Start with Module 2

Write Module 2 summaries early in development. This forces critical thinking about data gaps and study design. Continuously update Module 2 as new data becomes available.

βœ“Use Consistent Terminology

Use identical terminology across all modules. If Module 2 refers to "Study ABC-123," use that exact identifier in Module 5. Create a controlled vocabulary document.

βœ“Implement Robust Cross-Referencing

Every claim in Module 2 should reference supporting data in Modules 3-5. Use hyperlinks in eCTD to make navigation seamless. Validate all hyperlinks before submission.

βœ“Validate Early and Often

Use agency validation tools (FDA GST, EMA validator) throughout assembly, not just at the end. Fix structural issues early to avoid last-minute scrambles.

βœ“Maintain Document Traceability

Keep detailed records of document versions, authors, review status. Use document management systems with audit trails to comply with 21 CFR Part 11.

Common Pitfalls to Avoid

βœ—Broken Hyperlinks

One of the most common eCTD deficiencies. Always validate hyperlinks before submission. Broken links frustrate reviewers and delay approval.

βœ—Inconsistent Document Placement

Putting documents in wrong eCTD sections (e.g., stability data in 3.2.P.5 instead of 3.2.P.8). Follow ICH M4 structure precisely.

βœ—Non-Searchable PDFs

Scanned documents without OCR are difficult for reviewers to search. Always ensure PDFs are text-searchable, either by creating from source documents or running OCR on scans.

βœ—Inadequate Module 2 Summaries

Module 2 that simply lists studies without analysis. Summaries should synthesize data, identify trends, address concerns, and tell a cohesive story.

βœ—Last-Minute Assembly

Waiting until the end to compile the eCTD. Start early, build incrementally, and continuously validate. This reduces stress and improves quality.

Submission Checklist

Before submitting, verify:

All required modules present and complete
XML backbone validates (agency tool)
All hyperlinks functional
PDFs are PDF/A format and searchable
File naming follows conventions
Module 1 region-specific forms complete
Study data in required format (CDISC if applicable)
Sequence numbering correct
All documents have correct operations (new/replace/delete)
MD5 checksums calculated and correct
Submission package size within limits
Cover letter and transmittal forms signed

Ready to Streamline Your eCTD Submissions?

See how DossiAIr automates ICH M4 eCTD structure creation with AI-powered intelligence